Event-Driven Stocks

F-star Therapeutics, Inc.

Healthcare · Pharmaceutical Preparations · DE · SEC filings ↗ · Compare ⊕

Signs● 4 good● 3 warningdetails ↓

Financials

SEC XBRL · annual
 FY21FY20FY19FY18FY17FY16
Revenue$21.2M$11.3M$28.3M———
Operating income−$30.7M−$22.4M−$33.0M−$28.5M−$21.3M−$19.4M
Net income−$31.3M−$25.6M−$24.1M−$22.9M−$27.7M−$17.4M
Total assets$123.0M$63.6M$63.2M$68.8M$52.3M$26.9M
Total liabilities$26.2M$20.6M$27.7M$13.0M$17.6M$9.9M
Equity$96.9M$43.0M$35.5M$55.9M$34.7M$17.0M
EPS (diluted)——$-1.46$-1.88$-2.48—
Shares out.9.1M16.5M16.4M13.0M9.4M9.4M

Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.

Key ratios

from filings · FY2021
Operating margin
−145.1%
Net margin
−147.8%
Return on equity
−32.3%
Return on assets
−25.4%
Return on capital (ROCE)
−27.7%
Liabilities / assets
21.3%
Debt / equity
0.27×
Book value / share
$10.64
Revenue growth (YoY)
88.1%
Net income growth (YoY)
—

Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.

Financial health

forensic scores · FY2021
Altman Z″ (distress)
4.00safe
Accruals / assets
−3.3%clean
Piotroski F-Score
6/9mixed

Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.

Quality score

EDS Score
60
/ 100
Profitability 0Growth 100Catalyst 33Earnings quality 67Financial strength 100

Our own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.

Signs

● 3 warning● 4 good
  • Operating losses (negative operating margin)
  • Reported a net loss
  • Negative operating cash flow
  • Revenue is growing year-over-year
  • Conservative leverage (liabilities < 50% of assets)
  • Clean earnings (low accruals)
  • Altman Z″ in the safe zone

Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.

Insider transactions

SEC Form 4 · most recent
2 acquisitions9 disposalsnet −377,145 shares · last 11
InsiderDateTypeSharesPrice
Kayitalire LouisOfficer — CHIEF MEDICAL OFFICERMar 8, 2023U29,236$7.12
Forster EliotOfficer — PRESIDENT AND CEOMar 8, 2023U347,578$7.12
Deptula-Hicks Darlene MOfficer — See RemarksMar 8, 2023U30,898$7.12
Brady Todd CDirectorMar 8, 2023U15,004$7.12
Brewis NeilOfficer — CHIEF SCIENTIFIC OFFICERMar 8, 2023U105,088$7.12
Race GeoffreyDirectorMar 8, 2023U3,937$7.12
Bermingham NessanDirectorMar 8, 2023U97,547$7.12
Benz Edward JrDirectorMar 8, 2023D4,385$7.12
Arkowitz DavidDirectorMar 8, 2023U8,386$7.12
Race GeoffreyDirectorJul 29, 2022Option exercise3,937$0.11
Forster EliotOfficer — President and CEOJul 29, 2022Option exercise260,977$0.11

Headline trade per Form 4 (officers, directors, 10%+ owners). Buy/sell read from the filing's structured data — blank where a field isn't cleanly tagged.

Material events

SEC Form 8-K · most recent

Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.

Recent SEC filings

All filings ↗

Event-driven situations (1)